Interestingly, even when the analysis is limited to BRCA1 mutation carriers, the pCR rate within this relatively homogenous BC subgroup varies between 20% and 61%, with both these extreme results obtained using apparently the same treatment regimen, e.g., cisplatin monotherapy (Table 4). The gene discussed is BRCA1; the disease is breast cancer.